Paclitaxel plus carboplatin in advanced non-small-cell lung cancer

A phase II trial

D. H. Johnson, D. M. Paul, K. R. Hande, Y. Shyr, C. Blanke, B. Murphy, M. Lewis, R. F. De Vore

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

Purpose: Studies conducted by the Eastern Cooperative Ontology Group (ECOG) indicate both paclitaxel and carboplatin are associated with an improvement in 1-year survival in patients with stage IV non-small-cell lung cancer (NSCLC). Based on these findings, a phase II trial of these agents in combination was conducted in patients with advanced NSCLC. Patients and Methods: Eligibility included previous untreated stage IIIB or IV NSCLC patients with a good performance status (PS). Paclitaxel (135 or 175 mg/m2) was administered by 24-hour infusion on day 1, followed by a 1-hour infusion of carboplatin on day 2 (300 mg/m2 or dosed to an area under the concentration-time curve [AUC] of 6 mg/mL · min). Treatment was repeated every 28 days for a total of six cycles. Hematopoietic growth factors were not routinely used. Results: Among 51 eligible patients, there were no complete and 14 partial responses, for an overall response rate of 27% (95% confidence interval [CI], 17% to 41%). The median progression-free survival time was 23.8 weeks (range, 12.1 to 73.9) and median survival time, 38 weeks. The survival rate at 1 year was 32%. Grade 3 or 4 granulocytopenia and thrombocytopenia were observed in 47% and 3%, respectively, of the 184 treatment cycles administered. The most common nonhematologic toxicities included nausea and emesis, neuropathy, and arthralgia/myalgia. Conclusion: Paclitaxel plus carboplatin is a moderately active regimen in patients with advanced NSCLC and warrants comparison with existing cisplatin-based regimens in a prospective randomized trial. The toxicities of this regimen are well tolerated in patients with a good PS.

Original languageEnglish (US)
Pages (from-to)2054-2060
Number of pages7
JournalJournal of Clinical Oncology
Volume14
Issue number7
StatePublished - 1996

Fingerprint

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Agranulocytosis
Survival
Myalgia
Arthralgia
Nausea
Cisplatin
Disease-Free Survival
Vomiting
Intercellular Signaling Peptides and Proteins
Survival Rate
Confidence Intervals
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Johnson, D. H., Paul, D. M., Hande, K. R., Shyr, Y., Blanke, C., Murphy, B., ... De Vore, R. F. (1996). Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial. Journal of Clinical Oncology, 14(7), 2054-2060.

Paclitaxel plus carboplatin in advanced non-small-cell lung cancer : A phase II trial. / Johnson, D. H.; Paul, D. M.; Hande, K. R.; Shyr, Y.; Blanke, C.; Murphy, B.; Lewis, M.; De Vore, R. F.

In: Journal of Clinical Oncology, Vol. 14, No. 7, 1996, p. 2054-2060.

Research output: Contribution to journalArticle

Johnson, DH, Paul, DM, Hande, KR, Shyr, Y, Blanke, C, Murphy, B, Lewis, M & De Vore, RF 1996, 'Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial', Journal of Clinical Oncology, vol. 14, no. 7, pp. 2054-2060.
Johnson, D. H. ; Paul, D. M. ; Hande, K. R. ; Shyr, Y. ; Blanke, C. ; Murphy, B. ; Lewis, M. ; De Vore, R. F. / Paclitaxel plus carboplatin in advanced non-small-cell lung cancer : A phase II trial. In: Journal of Clinical Oncology. 1996 ; Vol. 14, No. 7. pp. 2054-2060.
@article{e70617d07a794614b0d62049cd81ada9,
title = "Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial",
abstract = "Purpose: Studies conducted by the Eastern Cooperative Ontology Group (ECOG) indicate both paclitaxel and carboplatin are associated with an improvement in 1-year survival in patients with stage IV non-small-cell lung cancer (NSCLC). Based on these findings, a phase II trial of these agents in combination was conducted in patients with advanced NSCLC. Patients and Methods: Eligibility included previous untreated stage IIIB or IV NSCLC patients with a good performance status (PS). Paclitaxel (135 or 175 mg/m2) was administered by 24-hour infusion on day 1, followed by a 1-hour infusion of carboplatin on day 2 (300 mg/m2 or dosed to an area under the concentration-time curve [AUC] of 6 mg/mL · min). Treatment was repeated every 28 days for a total of six cycles. Hematopoietic growth factors were not routinely used. Results: Among 51 eligible patients, there were no complete and 14 partial responses, for an overall response rate of 27{\%} (95{\%} confidence interval [CI], 17{\%} to 41{\%}). The median progression-free survival time was 23.8 weeks (range, 12.1 to 73.9) and median survival time, 38 weeks. The survival rate at 1 year was 32{\%}. Grade 3 or 4 granulocytopenia and thrombocytopenia were observed in 47{\%} and 3{\%}, respectively, of the 184 treatment cycles administered. The most common nonhematologic toxicities included nausea and emesis, neuropathy, and arthralgia/myalgia. Conclusion: Paclitaxel plus carboplatin is a moderately active regimen in patients with advanced NSCLC and warrants comparison with existing cisplatin-based regimens in a prospective randomized trial. The toxicities of this regimen are well tolerated in patients with a good PS.",
author = "Johnson, {D. H.} and Paul, {D. M.} and Hande, {K. R.} and Y. Shyr and C. Blanke and B. Murphy and M. Lewis and {De Vore}, {R. F.}",
year = "1996",
language = "English (US)",
volume = "14",
pages = "2054--2060",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Paclitaxel plus carboplatin in advanced non-small-cell lung cancer

T2 - A phase II trial

AU - Johnson, D. H.

AU - Paul, D. M.

AU - Hande, K. R.

AU - Shyr, Y.

AU - Blanke, C.

AU - Murphy, B.

AU - Lewis, M.

AU - De Vore, R. F.

PY - 1996

Y1 - 1996

N2 - Purpose: Studies conducted by the Eastern Cooperative Ontology Group (ECOG) indicate both paclitaxel and carboplatin are associated with an improvement in 1-year survival in patients with stage IV non-small-cell lung cancer (NSCLC). Based on these findings, a phase II trial of these agents in combination was conducted in patients with advanced NSCLC. Patients and Methods: Eligibility included previous untreated stage IIIB or IV NSCLC patients with a good performance status (PS). Paclitaxel (135 or 175 mg/m2) was administered by 24-hour infusion on day 1, followed by a 1-hour infusion of carboplatin on day 2 (300 mg/m2 or dosed to an area under the concentration-time curve [AUC] of 6 mg/mL · min). Treatment was repeated every 28 days for a total of six cycles. Hematopoietic growth factors were not routinely used. Results: Among 51 eligible patients, there were no complete and 14 partial responses, for an overall response rate of 27% (95% confidence interval [CI], 17% to 41%). The median progression-free survival time was 23.8 weeks (range, 12.1 to 73.9) and median survival time, 38 weeks. The survival rate at 1 year was 32%. Grade 3 or 4 granulocytopenia and thrombocytopenia were observed in 47% and 3%, respectively, of the 184 treatment cycles administered. The most common nonhematologic toxicities included nausea and emesis, neuropathy, and arthralgia/myalgia. Conclusion: Paclitaxel plus carboplatin is a moderately active regimen in patients with advanced NSCLC and warrants comparison with existing cisplatin-based regimens in a prospective randomized trial. The toxicities of this regimen are well tolerated in patients with a good PS.

AB - Purpose: Studies conducted by the Eastern Cooperative Ontology Group (ECOG) indicate both paclitaxel and carboplatin are associated with an improvement in 1-year survival in patients with stage IV non-small-cell lung cancer (NSCLC). Based on these findings, a phase II trial of these agents in combination was conducted in patients with advanced NSCLC. Patients and Methods: Eligibility included previous untreated stage IIIB or IV NSCLC patients with a good performance status (PS). Paclitaxel (135 or 175 mg/m2) was administered by 24-hour infusion on day 1, followed by a 1-hour infusion of carboplatin on day 2 (300 mg/m2 or dosed to an area under the concentration-time curve [AUC] of 6 mg/mL · min). Treatment was repeated every 28 days for a total of six cycles. Hematopoietic growth factors were not routinely used. Results: Among 51 eligible patients, there were no complete and 14 partial responses, for an overall response rate of 27% (95% confidence interval [CI], 17% to 41%). The median progression-free survival time was 23.8 weeks (range, 12.1 to 73.9) and median survival time, 38 weeks. The survival rate at 1 year was 32%. Grade 3 or 4 granulocytopenia and thrombocytopenia were observed in 47% and 3%, respectively, of the 184 treatment cycles administered. The most common nonhematologic toxicities included nausea and emesis, neuropathy, and arthralgia/myalgia. Conclusion: Paclitaxel plus carboplatin is a moderately active regimen in patients with advanced NSCLC and warrants comparison with existing cisplatin-based regimens in a prospective randomized trial. The toxicities of this regimen are well tolerated in patients with a good PS.

UR - http://www.scopus.com/inward/record.url?scp=0029901788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029901788&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 2054

EP - 2060

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -